2020
DOI: 10.1016/j.ejps.2019.105169
|View full text |Cite
|
Sign up to set email alerts
|

Speed it up, slow it down…An issue of bicalutamide release from 3D printed tablets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 41 publications
(11 citation statements)
references
References 42 publications
0
11
0
Order By: Relevance
“…In our previous study, we investigated the 3D printing method by means of filament co-extrusion of drug-loaded filament and insoluble filament to obtain sustained-release dosage forms, from which the release profile of API can be changed “on demand” [ 34 ]. In the present study, we adapted this method to improve the dissolution rate of ketoprofen from tablets printed using the PVA-based filament containing 40% of the drug (F3) and water-soluble Kollicoat ® IR-based placebo filament.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In our previous study, we investigated the 3D printing method by means of filament co-extrusion of drug-loaded filament and insoluble filament to obtain sustained-release dosage forms, from which the release profile of API can be changed “on demand” [ 34 ]. In the present study, we adapted this method to improve the dissolution rate of ketoprofen from tablets printed using the PVA-based filament containing 40% of the drug (F3) and water-soluble Kollicoat ® IR-based placebo filament.…”
Section: Resultsmentioning
confidence: 99%
“…The co-extrusion printing is based on simultaneous extrusion of two materials using only one nozzle, which leads to the preparation of a printlet with a complex structure at the level of a single layer. The co-extrusion of API-loaded filament and insoluble placebo filaments leads to further modification of drug release, as compared with extrusion of a single filament [ 34 , 35 ].…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, the bioactivity of the drugs can be altered due to the melting temperature of the polymers to be extruded and to avoid this, it is relevant to select an appropriate drug, whose melting point is above one of the polymers [12]. By appropriately selecting the process parameters and material composition of the filament, it is possible to manufacture high-quality filaments containing the API (active pharmaceutical ingredient) [10,22]. Other drawbacks include a reduced choice of thermoplastic materials with good melting-viscosity properties for the extrusion process and the difficulty of loading thermo-sensitive drugs during the extrusion process caused by the high processing temperatures [5,11].…”
Section: Introductionmentioning
confidence: 99%
“…Notably, Figure 1 exemplifies that an equivalent number of module variants in the conventional and proposed concept yields different degrees of product variety (one product variant vs. > three product variants in the example shown), with greater product variety accessible with the proposed modular product concept. This is due to the fact that conventional modular product archetypes are usually constructed by fixed assembly of modules into products [ 17 , 40 , 53 , 59 , 60 , 61 ]. Variety in the product offering is typically attainable through iterative modifications of a single initial product design until arriving at the variant of choice.…”
Section: Introductionmentioning
confidence: 99%
“…The drawback with this approach is that approaching lower volumes and higher variety of products is accompanied by a loss of economies of scale and an inevitable trade-off between affordability and variety [ 23 ]. This explains why most demonstrated oral dosage form modularization, even when some variety is present, still either exhibits interdependent dosage form size, dose, and drug release kinetics and/or a choice between fixed dose and fixed drug release kinetics at a given dosage form size [ 17 , 52 , 58 , 59 , 62 , 63 , 64 , 65 , 66 , 67 ]. From a product variety management perspective, conventional modular concepts are therefore limited in their ability to simultaneously deliver both the high variety and affordability necessary for individualization.…”
Section: Introductionmentioning
confidence: 99%